<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229823</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0015</org_study_id>
    <nct_id>NCT04229823</nct_id>
  </id_info>
  <brief_title>Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD</brief_title>
  <acronym>BIGPRO</acronym>
  <official_title>Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (SCA3/MJD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will consist of a prospective observation of subjects in a natural history design.
      Disease progression will be monitored through clinical scales and video-oculography.
      Participants will be stratified in three groups: ataxic carriers, pre-ataxic carriers and
      non-carriers (controls). The following clinical scales will be applied in all subjects at
      baseline and at months 12 and 24: SARA, SCAFI, CCFS, NESSCA, INAS and ICARS. Oculomotor
      function will be registered using video-oculography (EyeSeeCam, InterAcoustics) at the same
      time points. Progression rates, effect sizes and responsiveness to change will be established
      for all parameters and results will be compared between candidate biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinocerebellar ataxia type 3, also called Machado-Joseph disease (SCA3/MJD), is an autosomal
      dominant neurodegenerative disorder caused by a CAG expansion (CAGexp) on ATXN3. Over 20
      years after the identification of the causal mutation, no form of prevention or treatment for
      this incapacitating condition was discovered. Similarly to other polyglutamine (polyQ)
      diseases, SCA3/MJD has a slow progression. Changes detected by clinical scales are small and,
      therefore, long intervals are needed to document disease progression. Clinical trials using
      clinical scales as primary outcomes should be very long, what makes them hardly feasible. In
      this context, the discovery of disease biomarkers is of utmost importance. Biomarkers
      associated with disease progression and/or with therapeutic intervention might be more easily
      verified than the changes measured by clinical scales. Seminal studies have demonstrated that
      oculomotor alterations and vestibulo-ocular reflex (VOR) impairment may be present even
      during presymptomatic periods. Our primary hypothesis is eye movement parameters including
      VOR, saccades, smooth pursuit and fixation measured by video-oculography could be biomarkers
      of SCA3/MJD disease progression. Besides that, the investigators aim to test if the candidate
      biomarkers present changes before disease-onset and if their responsiveness will be better
      than those of clinical scales, with more noticeable variations during a shorter period of
      time. The study will consist of a prospective observation of subjects in a natural history
      design. The investigators will monitor disease progression of the CAGexp carriers through
      clinical scales and video-oculography. At least 75 adult subjects from Rio Grande do Sul will
      be invited to participate in the study, and at least 50 of the participants will be
      asymptomatic subjects, at 50% risk of carrying the mutation. The study design will allow the
      subjects who wanted and the evaluators to stay blinded to subjects' genotypes. Participants
      will be stratified in three groups: ataxic carriers, pre-ataxic carriers and non-carriers
      (controls). Genotypes will be recorded separately to guarantee double blindness. For every
      pre-ataxic carrier, time until the disease-onset will be estimated by an equation previously
      built, in which individual age and CAGexp are the determinants. The following clinical scales
      will be applied in all subjects at baseline and at months 12 and 24: SARA, SCAFI, CCFS,
      NESSCA, INAS and ICARS. Oculomotor function will be registered in video and analyzed using
      the EyeSeeCam device. Progression rates of all variables will be estimated by mixed models,
      including as covariates age, groups and their interactions. Progression rates, effect sizes
      and responsiveness to change will be established for all parameters and results will be
      compared between candidate biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vestibulo-ocular reflex gain regression slope (VORr)</measure>
    <time_frame>24 months</time_frame>
    <description>Gain (Eye velocity/Head velocity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vertical smooth pursuit gain</measure>
    <time_frame>24 months</time_frame>
    <description>Regression slope of eye velocity versus target velocity during vertical smooth pursuit task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in slow-phase velocity of gaze evoked nystagmus (SPV-GE)</measure>
    <time_frame>24 months</time_frame>
    <description>Degrees/second</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the slope of peak duration versus amplitude of volitional vertical saccades</measure>
    <time_frame>24 months</time_frame>
    <description>egression slope between peak duration and saccade amplitude during volitional vertical saccades</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the slope of peak duration versus amplitude of reflexive vertical saccades</measure>
    <time_frame>24 months</time_frame>
    <description>Regression slope between peak duration and saccade amplitude during reflexive vertical saccades</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in slow-phase velocity of central nystagmus (SPV-C)</measure>
    <time_frame>24 months</time_frame>
    <description>Degrees/second</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Neurological Examination Score for Spinocerebellar Ataxia (NESSCA)</measure>
    <time_frame>24 months</time_frame>
    <description>Neurological examination score, varying between 0 and 40. Score increases with disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SCA Functional Index (SCAFI)</measure>
    <time_frame>24 months</time_frame>
    <description>Composite score. Score decreases with disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in International Cooperative Ataxia Rating Scale (ICARS)</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute score, varying between 0 and 100. Score increases with disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Inventory of Non-Ataxia Symptoms (INAS) count</measure>
    <time_frame>24 months</time_frame>
    <description>Scale varying between 0 and 16. Score increases with disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Composite Cerebellar Functional Severity Score (CCFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Composite score. Score increases with disease severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in horizontal smooth pursuit gain</measure>
    <time_frame>24 months</time_frame>
    <description>Gain (Eye velocity/Target velocity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reflexive vertical saccade velocity (RVSV)</measure>
    <time_frame>24 months</time_frame>
    <description>Degrees/second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in volitional vertical saccade velocity (VVSV)</measure>
    <time_frame>24 months</time_frame>
    <description>Degrees/second</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Machado-Joseph Disease</condition>
  <arm_group>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <description>Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <description>Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Related controls</arm_group_label>
    <description>Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Video-oculography</intervention_name>
    <description>Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical Scales</intervention_name>
    <description>All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).</description>
    <arm_group_label>Ataxic carriers</arm_group_label>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <description>Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)</description>
    <arm_group_label>Pre-ataxic carriers</arm_group_label>
    <arm_group_label>Related controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with molecular diagnosis of SCA3/MJD will be recruited from the Medical
        Genetics Service database of Hospital de Cl√≠nicas de Porto Alegre, Brazil, by telephone
        calls or by invitation in the outpatient clinic. First degree relatives of these subjects
        at 50% risk of carrying the mutation will also be invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with molecular diagnosis of SCA3/MJD

          -  Individuals at 50% risk of inheriting SCA3/MJD mutation without any clinical
             manifestation

        Exclusion Criteria:

          -  Other diagnosed neurological or vestibular condition

          -  Dyschromatopsia

          -  Refusal to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Jardim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Federal do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://bigpro.webnode.com/</url>
    <description>BIGPRO study website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Machado-Joseph Disease</keyword>
  <keyword>Spinocerebellar Ataxia Type 3</keyword>
  <keyword>SCA3</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Natural history</keyword>
  <keyword>Video-oculography</keyword>
  <keyword>Eye movement</keyword>
  <keyword>Surrogate biomarker</keyword>
  <keyword>Oculomotor neurophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will be done via direct contact with the Principal Investigator in order to preserve individual participants identities</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available after final statistical analysis and data publishing via direct contact with principal investigator</ipd_time_frame>
    <ipd_access_criteria>Investigators and researchers of the area</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

